More OncoSil Medical Ltd news
OncoSil Medical LtdASX: OSL

Positive Preliminary Results from PANCOSIL Phase 1-2 Study

Sep 17, 2025 at 11:23 PM EDT · Issued by OncoSil Medical Ltd

Filed with ASX · Sep 17, 2025 at 11:23 PM EDT

On 6ix: 6ix.com/news/positive-preliminary-results-from-pancosil-phase-1-2-study

Oncosil Medical Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

OncoSil Medical Ltd on 6ix

In the deck

  • OncoSil Medical — Investor Presentation (September 2025)14 slidesSep 18, 2025

Story so far

  • Completion of Recruitment in PANCOSIL StudyJul 4, 2025
  • OncoSil onboards first patient in PANCOSIL Clinical TrialNov 29, 2023
  • Ethics Committee Approves PANCOSIL Clinical TrialJun 5, 2023

Earlier from OncoSil Medical

  • Appendix 4E and Annual ReportAug 29, 2025
  • Completion of Recruitment in TRIPP-FFX Clinical TrialJul 22, 2025
  • Completion of Recruitment in PANCOSIL StudyJul 3, 2025
  • OSL announces $8.7m capital raise to drive commercialisationMay 26, 2025
  • Consolidation/Split - OSLMay 1, 2025

Later from OncoSil Medical

  • Response to ASX Aware LetterSep 29, 2025
  • OSPREY Analysis Shows Survival Benefit for OncoSil PatientsDec 2, 2025
  • OncoSil receives $1.84m R&D tax incentiveJan 7
  • Trading HaltJan 29
  • Quarterly Activities/Appendix 4C Cash Flow ReportJan 29
All OncoSil Medical news releases↗

Follow OncoSil Medical into a list and get an email when it puts out news.

Follow OncoSil Medical
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer